Application Areas


Inflammatory Bowel Disease
Colorectal Cancer
Future Applications

 

Latest News

July 2017: Preliminary results of DiagNodus Pilot Clinical Study on CRC prove DiagNodus concept for CRC detection


February 2017: Pilot Clinical Study on the use of DiagNodus approach for CRC detection initiated




February 2016: "Seal of Excellence" awarded to DiagNodus by the European Commission


 


 

Application Areas

Inflammatory Bowel Disease

Inflammatory bowel disease (IBD), largely comprising the two conditions, Crohn’s Disease and Ulcerative Colitis, is now emerging as a global health problem. It now affects about 3 million people in Europe and up to 620,000 in the UK (IBD Standards UK, 2013 Update). The symptoms of diarrhoea, abdominal pain and bloody stool substantially affect the quality of life of sufferers, and complications can be life threatening.   IBD is also strongly associated with colorectal cancer development risk.


Cytological appearance of samples collected using the DiagNodus method from a healthy volunteer (a) and patients with ulcerative colitis (b) and Crohn's disease (c)

The DiagNodus approach currently provides a simple, self-applied method for colorectal sample collection and reliable tests for determining bowel inflammation activity. These innovative techniques have been shown to be efficient for detecting IBD and distinguishing patients suffering from IBD from individuals with irritable bowel syndrome (a very common functional disorder producing similar symptoms). In addition, the DiagNodus technology can be used for assessing therapy effect in IBD patients who are undergoing treatment and monitoring those who are in remission (for detecting new disease flare-ups early).

Having established and clinically evaluated a range of tests involving laboratory analysis, the company is now developing a family of rapid point of care (POC) tests for IBD.

 

Colorectal Cancer

Colorectal cancer (CRC) is the second most common cause of cancer related death. About 1.4 million new CRC cases were diagnosed worldwide in 2012, mostly in developed countries.

The incidence of colorectal cancer is increasing in line with the ageing population.  Early detection is key to successful treatment of the disease and related cost management. An efficient screening strategy is essential to detect the disease early, when it often does not produce symptoms. The currently available faecal occult blood test (FOBT) is safe and inexpensive, but it does not detect non-bleeding tumours and its sensitivity is low.  Screening colonoscopies popular in the US are expensive to perform, extremely invasive and can sometimes cause serious complications.

The DiagNodus approach to the CRC detection is based upon measuring CRC biomarkers captured on a swab device self-applied by the patient.  The adoption of the approach would still require confirmatory diagnostic colonoscopies, but CRC detection rate should be considerably improved and numbers of unnecessary colonoscopies dramatically reduced.

DiagNodus has initiated its first pilot study targeting CRC in February 2017, and emerging early results look highly promising.


Future Applications

The colorectal sampling system developed by DiagNodus allows non-invasively collecting highly informative samples suitable for detecting a number of other important diseases.

In particular, collected colorectal mucus is a habitat of commensal microorganisms that are extremely important for normal functioning of the human gut. Therefore the use of this material in combination with modern microbiomic techniques can lead to the development of new diagnostic modalities for a range of common gastrointestinal diseases, especially diarrhoeas. This approach may also be very useful for investigating microbiome-associated causes of such general chronic conditions as autoimmune diseases, obesity and diabetes.

 

 

 


© DiagNodus 2017. All rights reserved. Terms of Use Policy. Privacy Policy
DiagNodus Ltd Registered in England number: 7600875 VAT Number: 121522366
Registered Office: 280 Babraham Research Campus, Cambridge, United Kingdom, CB22 3AT